Abstract
Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1182/blood.v130.suppl_1.429.429
Copy DOIJournal: Blood | Publication Date: Jun 25, 2021 |
Citations: 1 |
Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial
Join us for a 30 min session where you can share your feedback and ask us any queries you have